Report cover image

Ventricular Tachycardia (V-tach or VT) Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20147084

Description

Studies reveal that ventricular tachycardia and ventricular fibrillation are responsible for the majority of cases of sudden cardiac death, accounting for 300,000 deaths  annually in the United States. Ventricular tachycardia is also reported to have a strong association with coronary artery disease, with an estimated 15% of the patients affected by coronary artery disease having ventricular tachycardia. The rising burden of cardiovascular conditions is increasing the incidence of ventricular tachycardia, which is expected to fuel the demand for effective therapeutic interventions.

Report Coverage

The Ventricular Tachycardia (V-tach or VT) Drug Pipeline Report by Expert Market Research gives comprehensive insights into ventricular tachycardia (V-tach or VT) drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ventricular tachycardia (V-tach or VT). The report includes the analysis of over 100 pipeline drugs and 50+ companies. The ventricular tachycardia (V-tach or VT) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from ventricular tachycardia (V-tach or VT).

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing ventricular tachycardia (V-tach or VT) pipeline development activities.

Ventricular Tachycardia (V-tach or VT) Drug Pipeline Outlook

Ventricular tachycardia is defined as a fast, irregular heart rate that occurs in the lower chambers of the heart (ventricles), constituting three or more consecutive heartbeats at a rate of over 100 per minute. The condition is a potentially fatal arrhythmia and is responsible for a substantial percentage of sudden cardiac deaths in the United States. Ischemic heart disease is considered the most common cause of ventricular tachycardia.

Ventricular tachycardia (V-tach or VT) treatment is primarily focused on stabilizing the heart rhythm, preventing recurrence, and managing underlying causes. Antiarrhythmic drugs such as amiodarone, lidocaine, and procainamide are commonly used for preventing episodes of ventricular tachycardia. Advancements in understanding the electrical pathways of the heart are facilitating the identification of novel drug targets, which are likely to positively impact the ventricular tachycardia (V-tach or VT) pipeline landscape in the coming years.

Ventricular Tachycardia (V-tach or VT) – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of ventricular tachycardia (V-tach or VT) drug candidates based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class

EMR’s ventricular tachycardia (V-tach or VT) therapeutic assessment report covers 50+ drug analyses based on drug classes:
  • Antisense Oligonucleotide
  • Gene Therapy
  • Hormones
  • Neuropeptides
  • Oligonucleotides
  • Small Molecule
  • Triglyceride
By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
  • Oral
  • Parenteral
  • Others
Ventricular Tachycardia (V-tach or VT) – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase III covers a major share of the total clinical trials for ventricular tachycardia (V-tach or VT).

Ventricular Tachycardia (V-tach or VT) – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under ventricular tachycardia (V-tach or VT) pipeline analysis include antisense oligonucleotides, gene therapy, hormones, neuropeptides, oligonucleotides, small molecules, and triglycerides. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ventricular tachycardia (V-tach or VT).

Ventricular Tachycardia (V-tach or VT) Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR ventricular tachycardia (V-tach or VT) drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Ventricular Tachycardia (V-tach or VT) clinical trials:
  • Cardurion Pharmaceuticals, Inc.
  • Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
  • Milestone Pharmaceuticals Inc.
  • Varian (a Siemens Healthineers Company)
  • Adagio Medical
  • Boston Scientific Corporation
  • AtaCor Medical, Inc.
  • Thermedical, Inc.
Ventricular Tachycardia (V-tach or VT) – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for ventricular tachycardia (V-tach or VT). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of ventricular tachycardia (V-tach or VT) drug candidates.

Drug: Etripamil NS 70 mg

The objective of this multi-center, double-blind, placebo-controlled study is to assess the safety profile and efficacy of etripamil nasal spray (NS) self-administered by an estimated 500 patients who experience paroxysmal supraventricular tachycardia episodes in an at-home setting. The study is sponsored by Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. and is in Phase III clinical development.

Drug: CRD-4730

Cardurion Pharmaceuticals, Inc. is conducting a Phase 2 study to investigate the pharmacokinetics, safety, tolerability, and pharmacodynamics of the ventricular tachycardia (V-tach or VT) drug candidate CRD-4730 in catecholaminergic polymorphic ventricular tachycardia (CPVT) patients. The study has enrolled around 12 participants and is expected to be completed by September 2026.

Reasons To Buy This Report

The Ventricular Tachycardia (V-tach or VT) Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for ventricular tachycardia (V-tach or VT). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into ventricular tachycardia (V-tach or VT) collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Ventricular Tachycardia (V-tach or VT) – Pipeline Insight Report
  • Which companies/institutions are leading the ventricular tachycardia (V-tach or VT) drug development?
  • What is the efficacy and safety profile of ventricular tachycardia (V-tach or VT) pipeline drugs?
  • Which company is leading the ventricular tachycardia (V-tach or VT) pipeline development activities?
  • What is the current ventricular tachycardia (V-tach or VT) commercial assessment?
  • What are the opportunities and challenges present in the ventricular tachycardia (V-tach or VT) drug pipeline landscape?
  • What is the efficacy and safety profile of ventricular tachycardia (V-tach or VT) pipeline drugs?
  • Which company is conducting major trials for ventricular tachycardia (V-tach or VT) drugs?
  • Which companies/institutions are involved in ventricular tachycardia (V-tach or VT) collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in ventricular tachycardia (V-tach or VT)?
Related Reports

Global Cardiovascular Drugs Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Ventricular Tachycardia (V-tach or VT)
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Ventricular Tachycardia
3.5 Diagnosis
3.6 Treatment
4 Patient Profile: Ventricular Tachycardia (V-tach or VT)
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Ventricular Tachycardia (V-tach or VT): Epidemiology Snapshot
5.1 Ventricular Tachycardia (V-tach or VT) Incidence by Key Markets
5.2 Ventricular Tachycardia (V-tach or VT) – Patients Seeking Treatment in Key Markets
6 Ventricular Tachycardia (V-tach or VT): Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Ventricular Tachycardia (V-tach or VT): Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Ventricular Tachycardia (V-tach or VT), Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Ventricular Tachycardia (V-tach or VT) Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Ventricular Tachycardia (V-tach or VT) Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Etripamil NS 70 mg
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: Dexmedetomidine, Drug: Normal saline
10.2.3 Drug: Dantrolene/Ryanodex
10.2.4 Other Drugs
11 Ventricular Tachycardia (V-tach or VT) Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Etripamil NS
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: CRD-4730
11.2.3 Other Drugs
12 Ventricular Tachycardia (V-tach or VT) Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug 1
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Ventricular Tachycardia (V-tach or VT) Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Ventricular Tachycardia (V-tach or VT), Key Drug Pipeline Companies
14.1 Cardurion Pharmaceuticals, Inc.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Milestone Pharmaceuticals Inc.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Varian (a Siemens Healthineers Company)
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Adagio Medical
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Boston Scientific Corporation
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 AtaCor Medical, Inc.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Thermedical, Inc.
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us